About Dermatophytic Onychomycosis
Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.
Technavios analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.
The market is divided into the following segments based on geography:
APAC
EMEA
Americas
Technavios report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Anacor Pharmaceuticals
Galderma
Janssen Biotech
Novartis
Valeant Pharmaceuticals
Other prominent vendors
Abeona Therapeutics
Allergan
Elorac
GlaxoSmithKline
Hexima
Hisamitsu Pharmaceutical
Mayne Pharma
MediQuest Therapeutics
Meiji Seika Pharma
Merz Pharma
Moberg Pharma
NanoBio
NovaBiotics
Nuvo Research
Pfizer
Polichem
Promius Pharma
Sanofi
Seren Pharmaceuticals
Taro Pharmaceutical
Topica Pharmaceuticals
Viamet Pharmaceuticals
Market driver
Increase in R&D
For a full, detailed list, view our report
Market challenge
Adverse effects and limited efficacy of drugs
For a full, detailed list, view our report
Market trend
Increased focus on combination therapies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Product offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Overview: Dermatophytic onychomycosis
Types of dermatophytic onychomycosis
Risk factors
Management
Epidemiology
PART 06: Pipeline analysis
TDT 067
P-3058
MOB-015
VT-1161
Luliconazole solution, 10%
ME1111
NP213
HXP124
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by route of administration
Topical
Oral
PART 09: Geographical segmentation
Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
Dermatophytic onychomycosis market in Americas
Dermatophytic onychomycosis market in EMEA
Dermatophytic onychomycosis market in APAC
PART 10: Market drivers
Increase in R&D
Growing prevalence of dermatophytic onychomycosis
Unmet medical needs
Rise in prevalence of diabetes
PART 11: Impact of drivers
PART 12: Market challenges
Adverse effects and limited efficacy of drugs
Lack of awareness
Increased availability of generics and alternative therapies
Product recalls by US FDA
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies
Outsourcing of drugs manufacturing
Increase in strategic alliances among vendors
Incorporation of novel technology for product development
PART 15: Vendor landscape
Competitive scenario
Anacor Pharmaceuticals
Galderma
Janssen Biotech
Novartis
Valeant Pharmaceuticals
Other prominent vendors
PART 16: Appendix
List of abbreviations
PART 17: Explore Technavio
List of Exhibits
Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
Exhibit 02: Percentage of population undergoing treatment globally 2015
Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Comparison of activity of topical medications for onychomycosis
Exhibit 09: Comparison of activity of oral medications for onychomycosis
Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: Anacor Pharmaceuticals: Key takeaways
Exhibit 22: Galderma: Key takeaways
Exhibit 23: Janssen Biotech: Key takeaways
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Valeant Pharmaceuticals: Key takeaways
